Global Reach OraSure sells its portfolio worldwide to clinical laboratories, hospitals, physician offices, clinics, public health and community organizations, research institutions, government agencies, pharma and direct to consumers, indicating broad cross-industry demand and multiple entry points for partnerships or expanded product lines.

Home and Point-of-Care Strategic emphasis on at-home self-collection and point-of-need testing, evidenced by products like Colli-Pee Dx and its recent integration with Roche cobas high-throughput testing, signaling opportunities for IVD collaborations, remote diagnostics programs, and at-home testing product bundles.

Technology Leverage Adoption of advanced stabilization and assay chemistry (NucleoPrecision) and a tech stack including Power BI, SAP, SQL Server, and cloud collaboration tools suggests suitability for value-based selling around workflow efficiency, data analytics, and scalable sample management solutions.

Leadership and Governance Board refreshment and new independent directors along with cooperative investor agreements indicate active governance and potential for strategic partnerships, co-development deals, and enhanced credibility with large health system buyers.

Financial Position Mid-range revenue bracket with healthy funding support and ongoing investor engagement create upside for expanding manufacturing capacity, clinical collaboration, and enterprise-scale contracts with laboratories and healthcare networks.